Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01052714
Other study ID # D7358-R
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date September 1, 2010
Est. completion date May 28, 2015

Study information

Verified date July 2018
Source VA Office of Research and Development
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This program aims to help Veterans who take antipsychotic medications lose weight. We use a program based on the American Diabetes Association's "Diabetes Prevention Program," and we have modified it to fit the lifestyles of people with mental illness. All participants are educated about nutrition and cutting down fat intake, how and when to exercise, and the causes of diabetes and how to prevent it. Participants must be Veterans who live within one hour of the Long Beach, West Los Angeles, Sepulveda, or West Los Angeles VA hospitals.


Recruitment information / eligibility

Status Completed
Enrollment 121
Est. completion date May 28, 2015
Est. primary completion date May 28, 2015
Accepts healthy volunteers No
Gender All
Age group 18 Years to 70 Years
Eligibility Inclusion Criteria:

- Must be a Veteran

- Diagnosis of psychotic disorders, schizophrenia, schizoaffective disorder and bipolar illness

- Age 18-70

- Clinically determined to require ongoing treatment with Second Generation Antipsychotics (SGA) such as olanzapine, risperidone, quetiapine, ziprasidone, aripiprazole, clozapine

- Experienced weight gain since treatment with SGA's

- Inpatient or outpatient at Long Beach, West Los Angeles, Sepulveda, or Downtown VA

- Competent to sign informed consent

Exclusion Criteria:

- Have recently been diagnosed with schizophrenia (less than 1 year)

- Are pregnant or breast feeding a baby

- Have a medically unstable condition

Study Design


Related Conditions & MeSH terms


Intervention

Behavioral:
Lifestyle Balance
Patients assigned to the behavioral weight loss program (Lifestyle Balance Program) will do the following: -Meet with their psychiatrist and a nutritionist who will go over diet recommendations with the patient - Be given a 7% weight loss goal - Be assisted in obtaining a 500 calorie reduction per day -Exercise for at least 30 min/day, at least 5 days a week - Maintain weekly food and exercise diaries -Be quizzed on their knowledge of healthy eating habits and nutrition

Locations

Country Name City State
United States VA Long Beach Healthcare System, Long Beach, CA Long Beach California
United States VA Greater Los Angeles Healthcare System, Sepulveda, CA Sepulveda California
United States VA Greater Los Angeles Healthcare System, West Los Angeles, CA West Los Angeles California

Sponsors (1)

Lead Sponsor Collaborator
VA Office of Research and Development

Country where clinical trial is conducted

United States, 

References & Publications (3)

Erickson ZD, Kwan CL, Gelberg HA, Arnold IY, Chamberlin V, Rosen JA, Shah C, Nguyen CT, Hellemann G, Aragaki DR, Kunkel CF, Lewis MM, Sachinvala N, Sonza PA, Pierre JM, Ames D. A Randomized, Controlled Multisite Study of Behavioral Interventions for Veter — View Citation

Gelberg HA, Kwan CL, Mena SJ, Erickson ZD, Baker MR, Chamberlin V, Nguyen C, Rosen JA, Shah C, Ames D. Meal replacements as a weight loss tool in a population with severe mental illness. Eat Behav. 2015 Dec;19:61-4. doi: 10.1016/j.eatbeh.2015.06.009. Epub 2015 Jul 2. — View Citation

Kwan CL, Gelberg HA, Rosen JA, Chamberlin V, Shah C, Nguyen C, Pierre JM, Erickson ZD, Mena SJ, King M Jr, Arnold I, Baker MR, Meyer HB, Ames D. Nutritional counseling for adults with severe mental illness: key lessons learned. J Acad Nutr Diet. 2014 Mar;114(3):369-74. doi: 10.1016/j.jand.2013.12.005. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Mean Weight Change Per Week From Baseline to Termination Participants' weight was measured at each visit by study personnel using hospital scales, and the study groups' average weight changes per week were compared. Up to 19 observations per person, weekly for the first 2 months, then monthly for 10 months.
Primary Mean Waist Circumference Change Per Week From Baseline to Termination Participants' waist circumference was measured at each visit by study personnel using a measuring tape, and the study groups' average waist circumference changes per week were compared. Up to 19 observations per person, weekly for the first 2 months, then monthly for 10 months.
Primary Mean Body Mass Index (BMI) Change Per Week From Baseline to Termination Study personnel calculated each participant's BMI at each visit using their weight measurement taken at that visit and their height measurement taken at baseline. The study groups' average BMI changes per week were then compared. Up to 19 observations per person, weekly for the first 2 months, then monthly for 10 months.
Primary Mean Serum Insulin Level Change Per Week From Baseline to Termination Results obtained through VA facility's Outpatient Lab. The study groups' average serum level changes per week were then compared. Up to 5 observations per person, at baseline, 3 months, 6 months, 9 months, and 12 months.
Primary Mean Triglycerides Level Change Per Week From Baseline to Termination Results obtained through VA facility's Outpatient Lab. The study groups' average blood level changes per week were then compared. Up to 5 observations per person, at baseline, 3 months, 6 months, 9 months, and 12 months.
Primary Mean Low-Density Lipoprotein (LDL) Cholesterol Level Change Per Week From Baseline to Termination Results obtained through VA facility's Outpatient Lab. The study groups' average blood level changes per week were then compared. Up to 5 observations per person, at baseline, 3 months, 6 months, 9 months, and 12 months.
Primary Mean High-Density Lipoprotein (HDL) Cholesterol Level Change Per Week From Baseline to Termination Results obtained through VA facility's Outpatient Lab. The study groups' average blood level changes per week were then compared. Up to 5 observations per person, at baseline, 3 months, 6 months, 9 months, and 12 months.
Primary Health Knowledge Quiz Mean Total Score Change Per Week From Baseline to Termination Quiz of information covered during Lifestyle Balance classes, score range 0 - 30, worst to best. The study groups' average score changes per week were then compared. Up to 4 observations per person,at baseline, 2 months, 6 months, and 12 months.
Primary Change in Mean Total Calories Consumed Per Week From Baseline to Termination Caloric intake assessed by dietitians using participant-recorded weekly food and exercise journals. The study groups' average change in total calories consumed per week were then compared. Up to 19 observations per person, weekly for the first 2 months, then monthly for 10 months.
Primary Change in Mean Empty Calories Consumed Per Week From Baseline to Termination Caloric intake assessed by dietitians using participant-recorded weekly food and exercise journals. The study groups' average change in empty calories consumed per week were then compared. Up to 19 observations per person, weekly for the first 2 months, then monthly for 10 months.
Primary Change in Mean Total Exercise Time Per Week From Baseline to Termination Minutes exercised assessed by dietitians using participant-recorded weekly food and exercise journals. The study groups' average change in total minutes exercised per week were then compared. Up to 19 observations per person, weekly for the first 2 months, then monthly for 10 months.
Primary Mean University Rhode Island Change Assessment Scale (URICA) Total Score Change Per Week From Baseline to Termination Self-reported survey of respondents' feelings about changing their weight problem. Total score is also called the Readiness Score, ranging from -2 to +14 (worse to better), calculated by subtracting the mean from the precontemplation responses from the summation of the means of responses to contemplation, action, and the struggling to maintain items. Up to 4 observations per person, at baseline, 2 months, 6 months, and 12 months.
Primary WHO Quality of Life-BREF (WHOQOL-BREF) Mean Domain 1 Score Change Per Week From Baseline to Termination Self-reported survey of quality of life as related to respondents' physical health, score range 7-35, worst to best. The study groups' average subscore changes per week were then compared. Up to 4 observations per person, at baseline, 2 months, 6 months, and 12 months.
Primary WHO Quality of Life-BREF (WHOQOL-BREF) Mean Domain 2 Score Change Per Week From Baseline to Termination Self-reported survey of quality of life as related to respondents' psychological health, score range 6-30, worst to best. The study groups' average subscore changes per week were then compared. Up to 4 observations per person, at baseline, 2 months, 6 months, and 12 months.
Primary WHO Quality of Life-BREF (WHOQOL-BREF) Mean Domain 3 Score Change Per Week From Baseline to Termination Self-reported survey of quality of life as related to respondents' social relationships, score range 3-15, worst to best. The study groups' average subscore changes per week were then compared. Up to 4 observations per person, at baseline, 2 months, 6 months, and 12 months.
Primary WHO Quality of Life-BREF (WHOQOL-BREF) Mean Domain 4 Score Change Per Week From Baseline to Termination Self-reported survey of quality of life as related to respondents' environment, score range 8-40, worst to best. The study groups' average subscore changes per week were then compared. Up to 4 observations per person, at baseline, 2 months, 6 months, and 12 months.
Primary Brief Psychiatric Rating Scale (BPRS) Mean Total Score Change Per Week From Baseline to Termination Clinician-assessed symptom survey, score range 18 - 126, best to worst. The study groups' average score changes per week were then compared. Up to 4 observations per person, at baseline, 2 months, 6 months, and 12 months.
Primary Beck Anxiety Inventory (BAI) Mean Total Score Change Per Week From Baseline to Termination Self-reported symptom survey, score range 0 - 63, best to worst. The study groups' average score changes per week were then compared. Up to 4 observations per person, at baseline, 2 months, 6 months, and 12 months.
See also
  Status Clinical Trial Phase
Recruiting NCT04243317 - Feasibility of a Sleep Improvement Intervention for Weight Loss and Its Maintenance in Sleep Impaired Obese Adults N/A
Recruiting NCT04101669 - EndoBarrier System Pivotal Trial(Rev E v2) N/A
Terminated NCT03772886 - Reducing Cesarean Delivery Rate in Obese Patients Using the Peanut Ball N/A
Completed NCT03640442 - Modified Ramped Position for Intubation of Obese Females. N/A
Completed NCT04506996 - Monday-Focused Tailored Rapid Interactive Mobile Messaging for Weight Management 2 N/A
Recruiting NCT06019832 - Analysis of Stem and Non-Stem Tibial Component N/A
Active, not recruiting NCT05891834 - Study of INV-202 in Patients With Obesity and Metabolic Syndrome Phase 2
Active, not recruiting NCT05275959 - Beijing (Peking)---Myopia and Obesity Comorbidity Intervention (BMOCI) N/A
Recruiting NCT04575194 - Study of the Cardiometabolic Effects of Obesity Pharmacotherapy Phase 4
Completed NCT04513769 - Nutritious Eating With Soul at Rare Variety Cafe N/A
Withdrawn NCT03042897 - Exercise and Diet Intervention in Promoting Weight Loss in Obese Patients With Stage I Endometrial Cancer N/A
Completed NCT03644524 - Heat Therapy and Cardiometabolic Health in Obese Women N/A
Recruiting NCT05917873 - Metabolic Effects of Four-week Lactate-ketone Ester Supplementation N/A
Active, not recruiting NCT04353258 - Research Intervention to Support Healthy Eating and Exercise N/A
Completed NCT04507867 - Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III N/A
Recruiting NCT03227575 - Effects of Brisk Walking and Regular Intensity Exercise Interventions on Glycemic Control N/A
Completed NCT01870947 - Assisted Exercise in Obese Endometrial Cancer Patients N/A
Recruiting NCT06007404 - Understanding Metabolism and Inflammation Risks for Diabetes in Adolescents
Recruiting NCT05972564 - The Effect of SGLT2 Inhibition on Adipose Inflammation and Endothelial Function Phase 1/Phase 2
Recruiting NCT05371496 - Cardiac and Metabolic Effects of Semaglutide in Heart Failure With Preserved Ejection Fraction Phase 2